HIV drug Aptivus gains new indication approval for kids

Article

Boehringer Ingelheim's Aptivus can now be used to treat HIV-infected pediatric patients.

Pediatric patients between two and 18 years of age who are infected with HIV have a new treatment available to them. It’s Boehringer Ingelheim Pharmaceuticals’

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.